(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees...
Stats | |
---|---|
今日成交量 | 826 006 |
平均成交量 | 401 776 |
市值 | 53.67M |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0.177 (8.05%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-06-30 | Dalal Anupam | Buy | 7 400 | Common Stock |
2021-06-30 | Castelein Caley | Buy | 7 811 | Common Stock |
2021-06-30 | Cohen Cheryl | Buy | 8 140 | Common Stock |
2021-06-17 | Cohen Cheryl | Buy | 100 000 | Stock Option (Right to Buy) |
2021-03-31 | Cohen Cheryl | Buy | 8 020 | Common Stock |
INSIDER POWER |
---|
0.00 |
Last 63 transactions |
Buy: 4 252 497 | Sell: 3 402 072 |
音量 相关性
Aerpio Pharmaceuticals 相关性 - 货币/商品
Aerpio Pharmaceuticals 财务报表
Annual | 2022 |
营收: | $5.51M |
毛利润: | $-29.51M (-535.75 %) |
EPS: | $-1.080 |
FY | 2022 |
营收: | $5.51M |
毛利润: | $-29.51M (-535.75 %) |
EPS: | $-1.080 |
Financial Reports:
No articles found.
Aerpio Pharmaceuticals
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The company is headquartered in Blue Ash, Ohio and currently employs 27 full-time employees. The firm is focused on developing treatments for ocular disease. Its lead product candidate is AKB-9778. Its other two pipeline programs include AKB-4924 and ARP-1536. AKB-9778 is a small molecule activator of the Tie-2 pathway, which is being developed for the treatment of diabetic retinopathy (DR). AKB-4924 is a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha), which is being developed for the treatment of inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody directed at the same target as AKB-9778. ARP-1536 binds the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibiting its ability to interact with Tie-2. As of April 14, 2017, the Company had completed a Phase II trial of AKB-9778 in 144 patients with diabetic macular edema. As of April 14, 2017, the Company had completed Phase Ia clinical trial in healthy volunteers for AKB-4924.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。